Arun K. Ramani

Arun K. Ramani

Auto-generated profile, based on publicly available information

Arun K. Ramani

Centre for Computational Medicine, The Hospital for Sick Children, Toronto, ON, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2016 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
LHLindsey M. Hoffman
Lindsey M. Hoffman
MDMariko DeWire
Mariko DeWire
SRScott Ryall
Scott Ryall
PBPawel Buczkowicz
Pawel Buczkowicz
JLJames Leach
James Leach
MFMaryam Fouladi
Maryam Fouladi
Diffuse intrinsic pontine glioma (DIPG) and midline high-grade glioma (mHGG) are lethal childhood brain tumors. Spatial genomic heterogeneity has been well-described in adult HGG but has not been comprehensively characterized in pediatric HGG. We performed whole exome sequencing on 38-matched primary, contiguous, and metastatic tumor sites from eight children with DIPG (n = 7) or mHGG (n = 1) collected using a unique MRI-guided autopsy protocol. Validation was performed using Sanger sequencing, Droplet Digital polymerase-chain reaction, immunohistochemistry, and fluorescent in-situ hybridization. Median age at diagnosis was 6.1 years (range: 2.9–23.3 years). Median overall survival was 13.2 months (range: 11.2–32.2 months). Contiguous tumor infiltration and distant metastases were observed in seven and six patients, respectively, including leptomeningeal dissemination in three DIPGs. Histopathological heterogeneity was evident in seven patients, including intra-pontine heterogeneity in two DIPGs, ranging from World Health Organization grade II to IV astrocytoma. We found conservation of heterozygous K27M mutations in H3F3A (n = 4) or HIST1H3B (n = 3) across all primary, contiguous, and metastatic tumor sites in all DIPGs. ACVR1 (n = 2), PIK3CA (n = 2), FGFR1 (n = 2), and MET (n = 1) were also intra-tumorally conserved. ACVR1 was co-mutated with HIST1H3B (n = 2). In contrast, PDGFRA amplification and mutation were spatially heterogeneous, as were mutations in BCOR (n = 1), ATRX (n = 2), and MYC (n = 1). TP53 aberrations (n = 3 patients) varied by type and location between primary and metastatic tumors sites but were intra-tumorally conserved. Spatial conservation of prognostically-relevant and therapeutically-targetable somatic mutations in DIPG and mHGG contrasts the significant heterogeneity of driver mutations seen in adult HGG and supports uniform implementation of diagnostic biopsy in DIPG and mHGG to classify molecular risk groups and guide therapeutic strategy.

28 March 2023 in The American Journal of Human Genetics
Verified
Journal Article
Open access
ADAshish R. Deshwar
Ashish R. Deshwar
KYKyoko E. Yuki
Kyoko E. Yuki
HHHuayun Hou
Huayun Hou
YLYijing Liang
Yijing Liang
TKTayyaba Khan
Tayyaba Khan
JDJames J. Dowling
James J. Dowling
Genome sequencing (GS) is a powerful test for the diagnosis of rare genetic disorders. Although GS can enumerate most non-coding variation, determining which non-coding variants are disease-causing is challenging. RNA sequencing (RNA-seq) has emerged as an important tool to help address this issue, but its diagnostic utility remains understudied, and the added value of a trio design is unknown. We performed GS plus RNA-seq from blood using an automated clinical-grade high-throughput platform on 97 individuals from 39 families where the proband was a child with unexplained medical complexity. RNA-seq was an effective adjunct test when paired with GS. It enabled clarification of putative splice variants in three families, but it did not reveal variants not already identified by GS analysis. Trio RNA-seq decreased the number of candidates requiring manual review when filtering for de novo dominant disease-causing variants, allowing for the exclusion of 16% of gene-expression outliers and 27% of allele-specific-expression outliers. However, clear diagnostic benefit from the trio design was not observed. Blood-based RNA-seq can facilitate genome analysis in children with suspected undiagnosed genetic disease. In contrast to DNA sequencing, the clinical advantages of a trio RNA-seq design may be more limited.

4 May 2021 in Bioinformatics
Verified
Journal Article
Closed access
PDF file
MAMichael Apostolides
Michael Apostolides
YJYue Jiang
Yue Jiang
MHMia Husić
Mia Husić
RSRobert Siddaway
Robert Siddaway
CHCynthia Hawkins
Cynthia Hawkins
ARArun K Ramani
Arun K Ramani
Current fusion detection tools use diverse calling approaches and provide varying results, making selection of the appropriate tool challenging. Ensemble fusion calling techniques appear promising; however, current options have limited accessibility and function. MetaFusion is a flexible metacalling tool that amalgamates outputs from any number of fusion callers. Individual caller results are standardized by conversion into the new file type Common Fusion Format. Calls are annotated, merged using graph clustering, filtered and ranked to provide a final output of high-confidence candidates. MetaFusion consistently achieves higher precision and recall than individual callers on real and simulated datasets, and reaches up to 100% precision, indicating that ensemble calling is imperative for high-confidence results. MetaFusion uses FusionAnnotator to annotate calls with information from cancer fusion databases and is provided with a Benchmarking Toolkit to calibrate new callers. MetaFusion is freely available at https://github.com/ccmbioinfo/MetaFusion. Supplementary data are available at Bioinformatics online.

1 June 2020 in Nucleic Acids Research
Verified
Journal Article
Open access
SMSuluxan Mohanraj
Suluxan Mohanraj
JDJ Javier Díaz-Mejía
J Javier Díaz-Mejía
MPMartin D Pham
Martin D Pham
HEHillary Elrick
Hillary Elrick
MHMia Husić
Mia Husić
TPTrevor J Pugh
Trevor J Pugh
CReSCENT: CanceR Single Cell ExpressioN Toolkit (https://crescent.cloud), is an intuitive and scalable web portal incorporating a containerized pipeline execution engine for standardized analysis of single-cell RNA sequencing (scRNA-seq) data. While scRNA-seq data for tumour specimens are readily generated, subsequent analysis requires high-performance computing infrastructure and user expertise to build analysis pipelines and tailor interpretation for cancer biology. CReSCENT uses public data sets and preconfigured pipelines that are accessible to computational biology non-experts and are user-editable to allow optimization, comparison, and reanalysis for specific experiments. Users can also upload their own scRNA-seq data for analysis and results can be kept private or shared with other users.

1 August 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
JHJennifer A. Hoang
Jennifer A. Hoang
ACAlper Celik
Alper Celik
CLChristian Lupinek
Christian Lupinek
RVRudolf Valenta
Rudolf Valenta
LDLucy Duan
Lucy Duan
TEThomas Eiwegger
Thomas Eiwegger

9 March 2022
Verified
Journal Article
Open access
HDHannah G. Driver
Hannah G. Driver
THTaila Hartley
Taila Hartley
EPE. Magda Price
E. Magda Price
ATAndrei L. Turinsky
Andrei L. Turinsky
OBOrion J. Buske
Orion J. Buske
KBKym M. Boycott
Kym M. Boycott
Despite recent progress in the understanding of the genetic etiologies of rare diseases (RDs), a significant number remain intractable to diagnostic and discovery efforts. Broad data collection and sharing of information among RD researchers is therefore critical. In 2018, the Care4Rare Canada Consortium launched the project C4R-SOLVE, a subaim of which was to collect, harmonize, and share both retrospective and prospective Canadian clinical and multiomic data. Here, we introduce Genomics4RD, an integrated web-accessible platform to share Canadian phenotypic and multiomic data between researchers, both within Canada and internationally, for the purpose of discovering the mechanisms that cause RDs. Genomics4RD has been designed to standardize data collection and processing, and to help users systematically collect, prioritize, and visualize participant information. Data storage, authorization, and access procedures have been developed in collaboration with policy experts and stakeholders to ensure the trusted and secure access of data by external researchers. The breadth and standardization of data offered by Genomics4RD allows researchers to compare candidate disease genes and variants between participants (i.e., matchmaking) for discovery purposes, while facilitating the development of computational approaches for multiomic data analyses and enabling clinical translation efforts for new genetic technologies in the future.